Coave Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
34
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$33.3M
- Investors
-
19
Coave Therapeutics General Information
Description
Developer of genetic medicine technologies intended to address neurodegenerative diseases through targeted therapies. The company's platform is useful for delivering low doses of therapeutic genes like GBA1 and TFEB directly to the central nervous system, enhancing autophagy and lysosomal function, enabling researchers and healthcare providers to develop effective treatments for conditions such as ALS and other related disorders while improving patient outcomes and quality of life.
Contact Information
Website
www.coavetx.comCorporate Office
- 63bis avenue Ledru Rolin
- 75012 Paris
- France
Corporate Office
- 63bis avenue Ledru Rolin
- 75012 Paris
- France
Coave Therapeutics Timeline
Coave Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series A) | 09-Jan-2025 | $33.3M | Completed | Pre-Clinical Trials | ||
| 8. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 7. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 6. Later Stage VC | 15-Dec-2022 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series B) | 02-Dec-2021 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series B) | 18-Sep-2018 | Completed | Startup | |||
| 3. Early Stage VC (Series A) | 08-Jul-2016 | Completed | Startup | |||
| 2. Grant | 02-Jul-2015 | $167K | $905K | Completed | Startup | |
| 1. Early Stage VC (Series A) | 03-Mar-2015 | $905K | $905K | Completed | Startup |
Coave Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B Shares | ||||||||
| B Shares | ||||||||
| ABSA B | ||||||||
| ABSA A | 8,218 | $3.131646 | $1252.66 | $1252.66 | $1252.66 | 12.07% | ||
| Ordinary | 666 | $3.131646 | $1252.66 | $1252.66 | $1252.66 | 0.98% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Coave Therapeutics Comparisons
Industry
Financing
Details
Coave Therapeutics Competitors (39)
One of Coave Therapeutics’s 39 competitors is Verge Labs, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Verge Labs | Venture Capital-Backed | San Francisco, CA | ||||
| Cerevance | Venture Capital-Backed | Boston, MA | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| CuraSen | Venture Capital-Backed | San Carlos, CA |
Coave Therapeutics Patents
Coave Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026037731-A1 | Squaramide-modified viral vectors | Pending | 12-Aug-2024 | ||
| EP-4815999-A1 | Ionizable lipid nanoparticles | Pending | 01-Dec-2023 | ||
| WO-2025114520-A1 | Ionizable lipid nanoparticles | Inactive | 01-Dec-2023 | ||
| EP-4774001-A1 | Ionizable lipid nanoparticles | Pending | 07-Sep-2023 | ||
| WO-2025051994-A1 | Ionizable lipid nanoparticles | Inactive | 07-Sep-2023 | A61K49/0043 |
Coave Therapeutics Signals
Coave Therapeutics Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Invus (Private Equity) | PE/Buyout | Minority | ||
| Novo Holdings | Venture Capital | Minority | ||
| UI Investissement | PE/Buyout | Minority | ||
| Eure Kare | VC-Backed Company | Minority | ||
| Seroba Life Sciences | Venture Capital | Minority |
Coave Therapeutics Acquisitions (1)
Coave Therapeutics’s most recent deal was a Merger/Acquisition with Aloop Therapeutics. The deal was made on 02-Jun-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aloop Therapeutics | 02-Jun-2025 | Merger/Acquisition | Biotechnology |
Coave Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Aloop Therapeutics | Copenhagen, Denmark | 2022 |
Coave Therapeutics FAQs
-
When was Coave Therapeutics founded?
Coave Therapeutics was founded in 2014.
-
Where is Coave Therapeutics headquartered?
Coave Therapeutics is headquartered in Paris, France.
-
What is the size of Coave Therapeutics?
Coave Therapeutics has 34 total employees.
-
What industry is Coave Therapeutics in?
Coave Therapeutics’s primary industry is Drug Discovery.
-
Is Coave Therapeutics a private or public company?
Coave Therapeutics is a Private company.
-
What is Coave Therapeutics’s current revenue?
The current revenue for Coave Therapeutics is .
-
How much funding has Coave Therapeutics raised over time?
Coave Therapeutics has raised $80.8M.
-
Who are Coave Therapeutics’s investors?
Invus (Private Equity), Novo Holdings, UI Investissement, Eure Kare, and Seroba Life Sciences are 5 of 19 investors who have invested in Coave Therapeutics.
-
Who are Coave Therapeutics’s competitors?
Verge Labs, Cerevance, ONL Therapeutics, Neurona Therapeutics, and CuraSen are some of the 39 competitors of Coave Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process